From March 28th to 31st, 2024, the 29th Academic Conference of the Chinese Medical Association Pathology Branch and the 13th Pathology Annual Meeting were held at the Beijing National Convention Center. Medical experts, scholars, and representatives from domestic and international enterprises gathered to discuss academic experiences and industry dynamics in pathological diagnosis. During this grand event, the SpaceGen "New Advances in Genetic Testing for Gynecologic Tumors" academic symposium was successfully held.

Event Recap

This satellite symposium was jointly hosted by Professor Liu Dongge from Beijing Hospital and Professor Wang Zhe from the Fourth Military Medical University's Xijing Hospital, with Professor Zhou Xianrong from the Obstetrics and Gynecology Hospital affiliated with Fudan University serving as the sharing guest. The venue was filled with distinguished guests and experts, generating unprecedented enthusiasm and sparking extensive attention and lively discussions among medical experts. The conference was a complete success!

Speech by Professor Liu Dongge

At the beginning of the academic symposium, Professor Liu Dongge delivered a speech, stating that as one of the leading enterprises in the field of tumor diagnosis, SpaceGen has been diligently working on genetic testing for gynecologic tumors. They have successively launched various NGS testing technologies and products for gynecologic tumors, such as "Human Endometrial Cancer Molecular Classification Detection Kit," "Human Ovarian Cancer Gene Mutations Detection Kit," " BRCA1/2 Gene Mutations Detection Kit," and "Human PAX1 Gene Methylation Detection Kit." He expressed hope that SpaceGen will continue to focus on the development and application of molecular pathological testing technology to assist clinical diagnosis and treatment. Finally, he wished the satellite symposium a complete success and encouraged all attendees to express their opinions freely.

Speech by Professor Wang Zhe

Professor Wang Zhe warmly welcomed the attendees and reiterated the importance of genetic testing. He emphasized that genetic testing is essential for molecular subtyping diagnosis, predicting genetic risks, monitoring efficacy, suggesting drug resistance, and selecting treatment plans. He hoped to discuss with medical experts present the challenges and opportunities in the development of gynecology medicine, share experiences and explorations, draw sparks of knowledge, expand the boundaries of thinking, and promote the development of gynecology medicine to a higher level.

Theme Sharing by Professor Zhou Xianrong

Gene detection technology has shown promising application prospects and broad development in early screening of female tumors, guiding drug selection, predicting prognosis, and monitoring efficacy. In the academic sharing session, Professor Zhou Xianrong elaborated on the clinical significance and application of genetic testing in guiding precise diagnosis and treatment of ovarian cancer, endometrial cancer, and cervical cancer patients.

Professor Zhou Xianrong pointed out that gynecologic tumor pathology has entered the molecular era, and molecular subtyping of endometrial cancer has been widely studied and concerned by scholars worldwide since its proposal. Molecular subtyping is of great significance for the conservative treatment and surgical scope selection of endometrial cancer, the selection of postoperative adjuvant treatment, and prognosis judgment. Therefore, he recommended that all diagnosed endometrial cancer patients undergo molecular subtyping testing under conditions.

Furthermore, Professor Zhou Xianrong introduced that it is necessary for diagnosed ovarian cancer patients to undergo genetic testing, which guides the selection of subsequent treatment plans and prognosis judgment, thereby achieving individualized and precise treatment of ovarian cancer. Standardized chemotherapy and targeted drug maintenance therapy support patients to survive beyond a 5-year period.

Cervical cancer is one of the most common malignant tumors in women, always ranking at the forefront of gynecologic malignancies, and more than 90% of cervical cancer cases are caused by HPV infection. Professor Zhou Xianrong pointed out in the sharing session that circulating free DNA (cfDNA) is a potential abundant source of tumor biomarkers, especially in the early diagnosis and prognosis of cervical cancer, possessing unique specificity and enormous potential value.

In addition to academic exchanges, we also organized a lottery session, with Professors Zhou Xianrong and Liu Aijun serving as lottery guests. Representatives from Weinan Second Hospital and the People's Hospital of Tibet Autonomous Region won the lottery, winning the top prizes. The lottery session enhanced interaction and a joyful atmosphere among participants, providing an opportunity for relaxation and promoting communication and friendship.

In this academic annual meeting and celebration, special thanks are due to the organizers for their strong support and assistance. It is due to the diligent efforts and organizational preparations of the organizers that this event has been successfully held.

Precision diagnosis and treatment, with testing as the forefront. SpaceGen has been diligently cultivating the field of tumor molecular diagnosis, adhering to a patient-centered approach, starting from clinical practical needs, and committed to transforming innovative technologies into compliant, high-quality molecular diagnostic products. In the future, SpaceGen will continue to strive tirelessly on the path of benefiting public health, endeavoring to promote the development of precision diagnosis and treatment.